The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enhancing the efficacy of anti-PD-L1 therapy by cabozantinib in the treatment of advanced esophageal squamous cell carcinoma (ESCC): Rationales from a preclinical study.
 
Jhe-Cyuan Guo
Honoraria - Astellas Pharma; Bayer; Ipsen; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech
Consulting or Advisory Role - Astellas Pharma; Merck Serono; Ono Pharmaceutical
Travel, Accommodations, Expenses - Ipsen; MSD; Novartis; Ono Pharmaceutical
 
Chun-Jung Chang
No Relationships to Disclose
 
Hung-Yang Kuo
No Relationships to Disclose
 
Ta-Chen Huang
No Relationships to Disclose
 
Hsi-Yu King
No Relationships to Disclose
 
Kuan-Ling Lin
No Relationships to Disclose
 
Hung-Wei Hsu
No Relationships to Disclose
 
Yu Yun Shao
Honoraria - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; Ipsen; Lilly; Merck; Ono Pharmaceutical; Roche
Speakers' Bureau - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; Lilly; Merck; Ono Pharmaceutical; Roche
Research Funding - AstraZeneca; Roche
Travel, Accommodations, Expenses - Roche
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Ipsen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche